Xtant Medical Holdings has announced a strategic partnership with B2i Digital aimed at enhancing investor understanding of its orthobiologics platform and long-term value proposition. This initiative will focus on delivering centralized, investor-oriented content to both retail and institutional audiences, showcasing Xtant Medical's leadership in regenerative medicine for orthopedic and neurosurgical applications.
David Shapiro, CEO of B2i Digital, pointed out the timing of this collaboration as Xtant Medical continues to expand its footprint in the orthobiologics market. The company's broad product range and consistent revenue growth underscore its potential as a key player in the medical technology sector. Sean Browne, CEO of Xtant Medical, stressed the importance of this partnership in effectively conveying the company's growth narrative and the intrinsic value of its biologics platform to the investment community.
With a reported fiscal year 2024 revenue of $117.5 million, a 29% increase from the previous year, Xtant Medical has solidified its financial standing. Its expansive market access, supported by 450 integrated delivery network contracts and a distribution network exceeding 670 independent distributors, firmly establishes its presence in the $2.5 billion U.S. orthobiologics market, a segment of the $10.1 billion global spine market.
